Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Minerva NeurosciencesAptevo TherapeuticsAdamas PharmaceuticalsCatalyst BiosciencesAnixa Biosciences
SymbolNASDAQ:NERVNASDAQ:APVONASDAQ:ADMSNASDAQ:CBIONASDAQ:ANIX
Price Information
Current Price$2.42$24.99$4.72$5.00$4.71
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.31.51.51.4
Analysis Score3.33.53.43.53.5
Community Score2.82.42.72.62.5
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.80.80.8
Earnings & Valuation Score0.00.60.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$6.75$32.00$12.25$17.00$11.00
% Upside from Price Target178.93% upside28.05% upside159.53% upside240.00% upside133.55% upside
Trade Information
Market Cap$103.39 million$111.18 million$144.28 million$156.66 million$127.79 million
Beta1.497.472.962.071.58
Average Volume613,59361,032693,403476,590604,798
Sales & Book Value
Annual RevenueN/A$32.42 million$54.64 million$10,000.00$250,000.00
Price / SalesN/A3.432.6415,665.50511.15
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.71 per share$3.66 per share($0.03) per share$5.68 per share$0.35 per share
Price / BookN/A6.83-157.330.8813.46
Profitability
Net Income$-72,180,000.00$-40,450,000.00$-105,190,000.00$-55,180,000.00$-10,020,000.00
EPS($1.85)($15.27)($3.80)($4.60)($0.59)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-89.12%N/AN/A
Return on Equity (ROE)-51.19%-345.40%N/A-55.23%-153.08%
Return on Assets (ROA)-29.75%-97.13%-43.47%-45.82%-129.89%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A11.44%N/AN/AN/A
Current Ratio6.49%4.13%3.94%6.42%7.88%
Quick Ratio6.49%4.13%3.72%6.42%7.88%
Ownership Information
Institutional Ownership Percentage66.28%14.06%44.23%63.81%7.68%
Insider Ownership Percentage12.00%10.88%19.70%4.00%23.30%
Miscellaneous
Employees1158138343
Shares Outstanding42.72 million4.45 million30.57 million31.33 million27.13 million
Next Earnings Date5/3/2021 (Estimated)5/12/2021 (Estimated)5/6/2021 (Estimated)5/10/2021 (Estimated)6/8/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Traders Purchase Large Volume of Anixa Biosciences Call Options (NASDAQ:ANIX)Traders Purchase Large Volume of Anixa Biosciences Call Options (NASDAQ:ANIX)
americanbankingnews.com - April 12 at 1:58 PM
Anixa Biosciences (NASDAQ:ANIX) Now Covered by Analysts at HC WainwrightAnixa Biosciences (NASDAQ:ANIX) Now Covered by Analysts at HC Wainwright
americanbankingnews.com - April 12 at 7:54 AM
Anixa and OntoChem to enter next stage of Covid-19 therapy developmentAnixa and OntoChem to enter next stage of Covid-19 therapy development
pharmaceutical-technology.com - April 6 at 11:43 AM
Anixa Biosciences, OntoChem ink pact to proceed to next stage of development of potential anti-viral therapy for Covid-19Anixa Biosciences, OntoChem ink pact to proceed to next stage of development of potential anti-viral therapy for Covid-19
pharmabiz.com - April 6 at 6:43 AM
Anixa and OntoChem enter next stage of Covid-19 anti-viral therapy developmentAnixa and OntoChem enter next stage of Covid-19 anti-viral therapy development
pharmaceutical-business-review.com - April 6 at 6:43 AM
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 TherapeuticAnixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
finance.yahoo.com - April 5 at 12:36 PM
Analyzing Anixa Biosciences (NASDAQ:ANIX) & Radius Health (NASDAQ:RDUS)Analyzing Anixa Biosciences (NASDAQ:ANIX) & Radius Health (NASDAQ:RDUS)
americanbankingnews.com - April 2 at 2:16 PM
Anixa Biosciences Stock Gives Every Indication Of Being Significantly OvervaluedAnixa Biosciences Stock Gives Every Indication Of Being Significantly Overvalued
finance.yahoo.com - March 28 at 1:09 PM
Anixa Biosciences Stock Is Estimated To Be Significantly OvervaluedAnixa Biosciences Stock Is Estimated To Be Significantly Overvalued
finance.yahoo.com - March 27 at 2:49 PM
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M. Baskies Buys 10,000 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M. Baskies Buys 10,000 Shares
americanbankingnews.com - March 25 at 10:20 PM
Amit Kumar Purchases 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockAmit Kumar Purchases 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock
americanbankingnews.com - March 25 at 8:20 PM
Anixa Biosciences Inc. [ANIX] moved down -29.31: Why It’s ImportantAnixa Biosciences Inc. [ANIX] moved down -29.31: Why It’s Important
dbtnews.com - March 25 at 6:15 PM
Anixa Biosciences Prices ~1.9M Share Common Stock Offering At $5.25/ShareAnixa Biosciences Prices ~1.9M Share Common Stock Offering At $5.25/Share
benzinga.com - March 22 at 11:12 PM
Anixa Biosciences Announces $10 Million Bought Deal Offering of Common StockAnixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock
finance.yahoo.com - March 22 at 6:11 PM
Anixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T TherapyAnixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy
finance.yahoo.com - March 22 at 9:22 AM
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine TechnologyAnixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
finance.yahoo.com - March 12 at 11:24 AM
Anixa Biosciences’ novel CAR-T cancer treatment technology receives European patentAnixa Biosciences’ novel CAR-T cancer treatment technology receives European patent
pharmabiz.com - March 6 at 9:47 AM
Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer TherapyAnixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy
finance.yahoo.com - March 4 at 9:30 AM
Scientific Research During A PandemicScientific Research During A Pandemic
forbes.com - March 3 at 9:38 AM
Experts Explain Why a Headache Is Normal After the COVID-19 Vaccine and How to Get ReliefExperts Explain Why a Headache Is Normal After the COVID-19 Vaccine and How to Get Relief
uk.style.yahoo.com - February 27 at 9:24 AM
Heres How Long Should You Wait to Get Vaccinated If Youve Already Had COVID-19Here's How Long Should You Wait to Get Vaccinated If You've Already Had COVID-19
msn.com - February 26 at 9:31 AM
Anixa Biosciences to Present at the H.C. Wainwright Global Life Sciences ConferenceAnixa Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - February 25 at 9:49 AM
Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic CandidatesAnixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates
finance.yahoo.com - February 16 at 10:25 AM
Increase in Incidence of Cancer Expected to Drive Global CAR-T Therapy Market: Ken ResearchIncrease in Incidence of Cancer Expected to Drive Global CAR-T Therapy Market: Ken Research
openpr.com - January 19 at 6:08 PM
Anixa Biosciences to Present at the B. Riley Oncology Investor ConferenceAnixa Biosciences to Present at the B. Riley Oncology Investor Conference
finance.yahoo.com - January 13 at 12:06 PM
DateCompanyBrokerageAction
9/11/2020Minerva NeurosciencesWilliam BlairReiterated Rating
7/2/2020Minerva NeurosciencesHC WainwrightReiterated Rating
7/1/2020Minerva NeurosciencesJMP SecuritiesReiterated Rating
6/1/2020Minerva NeurosciencesBTIG ResearchLower Price Target
5/29/2020Minerva NeurosciencesJefferies Financial GroupDowngrade
12/2/2019Minerva NeurosciencesChardan CapitalReiterated Rating
8/3/2018Minerva NeurosciencesCitigroupBoost Price Target
11/11/2020Aptevo TherapeuticsPiper SandlerReiterated Rating
3/4/2020Aptevo TherapeuticsRoth CapitalReiterated Rating
10/4/2019Aptevo TherapeuticsPiper Jaffray CompaniesLower Price Target
11/5/2018Aptevo TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
1/28/2021Adamas PharmaceuticalsNorthland SecuritiesBoost Price Target
1/14/2021Adamas PharmaceuticalsNeedham & Company LLCReiterated Rating
12/17/2019Adamas PharmaceuticalsCantor FitzgeraldReiterated Rating
12/9/2019Adamas PharmaceuticalsEvercore ISIReiterated Rating
9/30/2019Adamas PharmaceuticalsBank of AmericaDowngrade
8/9/2019Adamas PharmaceuticalsCowenSet Price Target
4/24/2019Adamas PharmaceuticalsMizuhoReiterated Rating
3/4/2021Catalyst BiosciencesRaymond JamesSet Price Target
11/5/2020Catalyst BiosciencesLifesci CapitalReiterated Rating
8/6/2020Catalyst BiosciencesCi CapitalReiterated Rating
1/4/2019Catalyst BiosciencesCIBCInitiated Coverage
1/4/2019Catalyst BiosciencesOppenheimerInitiated Coverage
6/21/2018Catalyst BiosciencesB. RileyDowngrade
2/15/2021Anixa BiosciencesAegisReiterated Rating
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.